Gastrointestinal Cancer

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

Robert J. Mayer, MD, who helped the field of oncology develop while conducting groundbreaking research, was honored in the Gastrointestinal Cancer category with a 2015 Giants of Cancer Care® award, a program that OncLive developed to recognize leaders in the field.

Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.

Tivantinib failed to improve overall survival compared with placebo as a second-line therapy for patients with MET-overexpressing inoperable hepatocellular carcinoma in the phase III METIV-HCC study.

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

The addition of a platinum agent to standard gemcitabine and nab-paclitaxel was found to be associated with impressive response and overall survival rates in patients with stage IV pancreatic cancer.

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

The combination regimen of the PD-1 inhibitor nivolumab (Opdivo) plus nab-paclitaxel and gemcitabine was found to demonstrate encouraging clinical activity and low toxicity levels in patients with metastatic pancreatic cancer.